Description
Dasatinib
Each film-coated tablet contains Dasatinib monohydrate 20.74 mg equivalent to Dasatinib…………………20mg.
INDICATION
LuciDasa is a kinase inhibitor indicated for the treatment of : • Newly diagnosed adults with Philadelphia chromosome -positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. • Adults with Philadelphia chromosome -positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. • Pediatric patients 1 year of age and older with Ph+ CML in chronic phase. • Pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.
DOSAGE AND USE
• Chronic phase CML in adults: 100 mg once daily. • Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults: 140 mg once daily. • Chronic phase CML and ALL in pediatrics: starting dose based on body weight. • Administer orally, with or without a meal. Do not crush, cut, or chew tablets.
STORAGE
In a dry place and store at 20℃ to 25℃.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciDasa during Pregnancy and Lactation.
PLEASE SEE PACKAGE INSERT
Dasatinib
Each film-coated tablet contains Dasatinib monohydrate 50.74 mg equivalent to Dasatinib…………………50mg.
INDICATION
LuciDasa is a kinase inhibitor indicated for the treatment of : • Newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. • Adults with Philadelphia chromosome -positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. • Pediatric patients 1 year of age and older with Ph+ CML in chronic phase. • Pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.
DOSAGE AND USE
• Chronic phase CML in adults: 100 mg once daily. • Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults: 140 mg once daily. • Chronic phase CML and ALL in pediatrics: starting dose based on body weight. • Administer orally, with or without a meal. Do not crush, cut, or chew tablets.
STORAGE
In a dry place and store at 20℃ to 25℃.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciDasa during Pregnancy and Lactation.
PLEASE SEE PACKAGE INSERT
Dasatinib
Each film-coated tablet contains Dasatinib monohydrate 70.74 mg equivalent to Dasatinib…………………70mg.
INDICATION
LuciDasa is a kinase inhibitor indicated for the treatment of : • Newly diagnosed adults with Philadelphia chromosome -positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. • Adults with Philadelphia chromosome -positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. • Pediatric patients 1 year of age and older with Ph+ CML in chronic phase. • Pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.
DOSAGE AND USE
• Chronic phase CML in adults: 100 mg once daily. • Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults: 140 mg once daily. • Chronic phase CML and ALL in pediatrics: starting dose based on body weight. • Administer orally, with or without a meal. Do not crush, cut, or chew tablets.
STORAGE
In a dry place and store at 20℃ to 25℃.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciDasa during Pregnancy and Lactation.
Reviews
There are no reviews yet.